Newron Pharmaceuticals Reports H1 2026 Results

Newron Pharmaceuticals S.p.A. has released its financial results for the first half of 2026, highlighting substantial progress in the development of evenamide, a treatment for schizophrenia. The company reports a net loss of EUR 16.4 million due to increased R&D expenses which rose to EUR 14.6 million from EUR 6.1 million the previous year. Revenues dropped to EUR 3.2 million from EUR 11.9 million in 2025, attributed to the prior year's milestone payments.

The ENIGMA-TRS program remains on track, with ENIGMA-TRS 1 nearing its enrollment target. ENIGMA-TRS 2 is set to resume US enrollment following FDA discussions. Additionally, Newron secured a EUR 38 million financing agreement to bolster its financial stance.

Newron's strategic actions, including patent extensions and foreign partnerships, solidify its foothold in the pharmaceutical landscape amid ongoing clinical trials and corporate developments.